Accreditation
In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and Harborside Medical Education. The Annenberg Center is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Continuing Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Annenberg Center designates this live activity for a maximum of 13.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Annenberg Center designates this live activity for a maximum of 13.0 ANCC contact hours.
The Annenberg Center designates this live activity for a maximum of 13.0 contact hours (0.130 CEUs) of continuing pharmacy credit. Credit will be provided to the NABP CPE Monitor within 60 days after the activity completion.
The Annenberg Center for Health Sciences at Eisenhower has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 13.0 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Continuing Education Credit
To be eligible for documentation of credit, participants must attend the full activity and submit a completed evaluation form. Participants must complete the evaluation online by December 31, 2024.
Learning Objectives
Upon completion of this activity, participants should be better able to:
- Identify the latest management strategies for select solid tumors and hematologic malignancies, based on recent FDA approvals and practice guideline updates
- Assess the clinical relevance of efficacy and safety data from recently published studies of cancer therapies
- Recognize and manage adverse events (AEs) associated with newer systemic therapies to ensure patient safety and treatment adherence
- Apply collaborative approaches to patient-centered care in order to improve the quality of life of patients undergoing cancer treatment
- Analyze the role of surgical oncology in the context of multimodal treatment strategies to optimize disease control and survival outcomes
Intended Audience
The intended audience for this live conference is nurse practitioners, physician assistants, clinical nurse specialists, advanced degree nurses, hematology/oncology nurses, pharmacists, and clinicians who specialize in the field of oncology.
Conference Chair
Jason Astrin, DMSc, MBA, PA-C, DFAAPA, FAPO
The US Oncology Network
Planning Committee
Lorinda Coombs, PhD, CNS, FNP-BC, AOCNP®
University of North Carolina Chapel Hill School of Nursing and Lineberger Comprehensive Cancer Center
Rose DiMarco, PharmD, BCPS, BCOP
Sidney Kimmel Cancer Center at Thomas Jefferson University Hospital
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, BMTCN, FAAN, FAPO
Cleveland Clinic
Carolyn Grande, CRNP, AOCNP®, FAPO
Abramson Cancer Center, Hospital of the University of Pennsylvania
Andy Guinigundo, MSN, RN, CNP, ANP-BC, FAPO
Cincinnati Cancer Advisors
Lisa Hwa, APRN, DNP, CNP, FAPO
Mayo Clinic
Amber Koehler, MPAS, PA-C
Mayo Clinic
Lisa Kottschade, APRN, MSN, CNP, FAPO
Mayo Clinic
Heather Lewin, MSN, APRN
Flatiron Health
Haleigh Mistry, MS, PA-C
The University of Texas MD Anderson Cancer Center
Amy Pierre, MSN, ANP-C
Memorial Sloan Kettering Cancer Center and Flatiron Health
Beth Sandy, MSN, CRNP, FAPO
Abramson Cancer Center, Hospital of the University of Pennsylvania
Kate Taucher, PharmD, MHA, BCOP, FAPO
UCHealth Memorial Hospital
Disclosure Statement
It is the policy of the Annenberg Center for Health Sciences to ensure fair balance, independence, objectivity, and scientific rigor in all programming. All individuals with the potential to impact the content of an accredited education activity are expected to identify and reference off-label product use and disclose relevant financial relationships with ACCME-defined ineligible companies.
The Annenberg Center for Health Sciences assesses relevant financial relationships with its instructors, planners, managers, and other individuals who are in a position to control the content of CE activities. All relevant financial relationships that are identified are thoroughly vetted by the Annenberg Center for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. The Annenberg Center is committed to providing its learners with high-quality CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
In accordance with the Accreditation Council for Continuing Medical Education Standards, parallel documents from other accrediting bodies, and Annenberg Center for Health Sciences policy, the following disclosures have been made:
Jason Astrin has no relevant financial relationships to disclose.
Lorinda Coombs has no relevant financial relationships to disclose.
Rose DiMarco is on the Speakers Bureau for Lilly and Merck; and is a Clinical Thought Leader for CE Synergy’s Peak Exchange.
Beth Faiman is a consultant for BMS, GSK, Janssen, Pfizer, and Sanofi.
Carolyn Grande is on the Speakers Bureau and is a Consultant for Eisai and Merck.
Andy Guinigundo is a consultant for Amgen, Jazz Pharma, and Pharmacosmos; and is on the Speaker’s Bureau for Amgen, Astellas, GSK, and Pfizer.
Lisa Hwa is on the Advisory Board for GSK, Janssen, and Shield.
Amber Koehler is on the Advisory Board for AbbVie, AstraZeneca, BMS, and Janssen.
Lisa Kottschade has no relevant financial relationships to disclose.
Heather Lewin owns stock in Roche.
Haleigh Mistry is on the Advisory Board for ADC Therapeutics and Genmab; is a Health Care Panelist for Genmab; is a Patient Education Consultant for ADC Therapeutics.
Amy Pierre is on the Advisory Board for Pfizer; is a Consultant for J & J; and owns stock in Roche.
Beth Sandy is on the Speakers Bureau for Amgen, AstraZeneca, Jazz, Lilly, Merck, and Takeda; is on the Advisory Board for Janssen; and is a Consultant for AbbVie.
Kate Taucher is on the Advisory Board for Amneal, AstraZeneca, and GSK; and is a Consultant for Advarra and Sandoz.
All other staff at the Annenberg Center and Harborside Medical Education have no relevant financial relationships to disclose.
All of the financial relationships listed for these individuals as well as those disclosed during the course of the activity have been mitigated.
Disclosure of Unlabeled Use
This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
